medigraphic.com
ISSN 0035-0052 (Print)

2017, Number 2

<< Back Next >>

Rev Mex Pediatr 2017; 84 (2)

Experience of treatment of neonatal persistent pulmonary hypertension in one medical center

González-López RA, Iglesias-Leboreiro J, Bernárdez-Zapata I, Rendón-Macías ME

Language: Spanish
References: 20
Page: 48-53
PDF size: 233.68 Kb.


ABSTRACT

Introduction: Persistent pulmonary hypertension (PPH) of the newborn is a common condition in neonatal therapies, especially when products are premature. Objective: To describe the therapeutic schemes used in PPH by gestational age groups. Material and methods: The treatments received by weeks of gestational age (WGA) groups (24-31, 32- 34, 35-37 and 38-40 WGA) were reviewed. Results: We studied 98 neonates. In 12 (12.2%) treatment was only with ventilation and metabolic support, the rest required at least one antihypertensive drug. The most commonly drugs used were: nitric oxide, sildenafil and milrinone. 39 (39.8%) required a combination. 53.1% (n = 51) were discharged with normal or mild hypertension pulmonary arterial pressure. There were 6 (6.1%) deaths. Patients with ‹ 32 WGA required more drugs to control pulmonary hypertension. Conclusion: Control of PPH is based on improving oxygenation and lung recruitment. Given the diversity of pharmacological treatments conducting multicenter clinical trials and developing clinical guidelines are needed.


REFERENCES

  1. Sharma V, Berkelhamer SK, Lakshminrusimha S. Persistent pulmonary hypertension of the newborn. Matern Health Neonatol Perinatol. 2015; 1: 14.

  2. Bendapudi P, Rao GG, Greenough A. Diagnosis and management of persistent pulmonary hypertension of the newborn. Paediatr Respir Rev. 2015; 16(3): 157-161.

  3. Steinhorn RH. Advances in neonatal pulmonary hypertension. Neonatology. 2016; 109(4): 334-344.

  4. Lakshminrusimha S, Konduri GG, Steinhorn RH. Considerations in the management of hypoxemic respiratory failure and persistent pulmonary hypertension in term and late preterm neonates. J Perinatol. 2016; 36(Suppl 2): S12-19.

  5. Jain A, McNamara PJ. Persistent pulmonary hypertension of the newborn: advances in diagnosis and treatment. Semin Fetal Neonatal Med. 2015; 20: 262-271.

  6. Nair J, Lakshminrusimha S. Update on PPHN: mechanisms and treatment. Sem Perinatol. 2014; 38(2): 78-91.

  7. Finer NN, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Sys Rev. 2006; 18(4): CD000399.

  8. Lakshminrusimha S, Mathew B, Leach CL. Pharmacologic strategies in neonatal pulmonary hypertension other than nitric oxide. Sem Perinatol. 2015; 40(3):160-73. doi: 10.1053/j. semperi.2015.12.004.

  9. Sola A, Baquero H. Sildenafilo oral en medicina neonatal “investigado para adultos, usado también por neonates”. An Pediatric. 2007; 66(2): 167-176.

  10. Pérez KM, Laughon M. Sildenafil in term and premature infants: a systematic review. Clin Ther. 2015; 37(11): 2598-2607.

  11. McNamara PJ, Shivananda SP, Sahni M, Freeman D, Taddio A. Pharmacology of milrinone in neonates with persistent pulmonary hypertension of the newborn and suboptimal response to inhaled nitric oxide. Pediatr Crit Care Med. 2013; 14(1): 74-84.

  12. Jame AT, Corcoran JD, McNamara PJ, Franklin O, EL-Khuffash AF. Effect of milrinone on right and left ventricular dysfunction when use as a rescue therapy for term infants with pulmonary hypertension. Cardiol Young. 2015; 25(1): 90-99.

  13. Van Loon RL, Roofthoofft MT, Hillege HL, ten Harkel AD, van Osch-Gevers M, Delhass T et al. Pediatric pulmonary hypertension in the netherlands epidemiology and characterization during the period 1991 to 2005. Circulation. 2011; 124: 1755-1764.

  14. Al Dabbagh M, Banjar H, Galal N, Kouatli A, Kandil H, Chehab M. Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary hypertension in children. Ann Thorac Med. 2014; 9(Suppl 1): S113-120.

  15. Abman SH, Hansmann G, Archer SL, Ivy DD, Adatia I, Chung WK, Hanna BD et al. Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society. Circulation. 2015; 132(21): 2037-2099.

  16. Filan PM, McDougall PN, Shekerdemian LS. Combination pharmacotherapy for severe neonatal pulmonary hypertension. J Paediatr Child Health. 2006; 42(2): 219-220.

  17. Abman SH. Inhaled nitric oxide for the treatment of pulmonary arterial hypertension. Handb Exp Pharmacol. 2013; 218: 257-276.

  18. Sayed A, Bisheer N. Outcome of oral sildenafil in neonatal persistent pulmonary hypertension of non-cardiac causes. J Neonatal Perinatal Med. 2015; 8(3): 215-220.

  19. Lakshminrusimha S, Keszier M. Persistent pulmonary hypertension of the newborn. Neoreviews. 2015; 16(12): e680-e692.

  20. Kahveci H, Yilmaz O, Avsar UZ, Ciftel M, Kilic O, Laloglu F et al. Oral sildenafil and inhaled iloprost in the treatment of pulmonary hypertension of the newborn. Pediatr Pulmonol. 2014; 49(12): 1205-1213.




2020     |     www.medigraphic.com